Sudeep Pharma Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/dc8ykzj9vkji97yuiquha2ly.pdf

Key Takeaways


The Quarter: Growth, Mix and the Margin Reset

Shanil Bhayani: "Since then, the customer ordering patterns have returned to the original forecast without any significant volume or margin impact."

The US Tariff Episode


NSS Acquisition: The European Accelerator

Shanil Bhayani: "And through the acquisition, what we've done is, we've cut out the five-year approval that we would have typically needed to enter the European market."

Direct Distribution: The Margin Bet


Battery Materials (pCAM): The Long-Dated Option

Shanil Bhayani: "So, what we have done is we have built a technology which is very low and effluent compared to the Chinese technology, still delivers at par or superior electrochemical performance that the customers need."

Balance Sheet & Working Capital


Competitive Moat

Shanil Bhayani: "In India today we would probably be the first and the largest doing this and apart from Sudeep in India and China there is very limited competition in this space purely because one the technology, second using the technology to get the functional ingredient correct and third is the regulatory approval and fourth but the most critical is the customer approval that you require to operate in this category."

Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth26% H1 growth rate sustained for full yearFY26
EBITDA margin floorMaintain above 35% going forwardOngoing
Gross marginSustain at historical average of 63-64%Ongoing
Working capital normalizationModerate to ~140-150 daysMedium term
Inventory stabilizationRotate back to historical levelsNext two quarters
Direct-sales investment payoffStart reflecting positively in marginsNext couple of quarters
Nandesari greenfield commissioningFifth facility onlineQ4 FY26
Nandesari revenue contributionMajority of business from existing capacity; meaningful greenfield contributionSecond half FY27, predominantly FY28
Dahej pCAM phase one25,000 metric tons capacity completedEarly CY27
pCAM meaningful revenueFrom Dahej greenfieldFY28
pCAM additional pilot capacityExisting food-grade line converted to battery gradeNext month or two

Key Metrics

MetricQ2 FY26
Total income₹172.8 cr, +15% YoY
EBITDA₹65.6 cr, flat YoY (vs ₹65.3 cr in Q2 FY25)
EBITDA margin38%, vs 43.3% in Q2 FY25 (per an analyst's math)
PAT₹46.8 cr, -4% YoY (vs ₹48.7 cr in Q2 FY25)
H1 FY26 total income₹302.9 cr, +31% YoY
H1 FY26 EBITDA margin37.9%, vs 40.9% in H1 FY25
H1 FY26 PAT₹78 cr, +19% YoY
International revenue share61% of H1 FY26 revenue
Specialty ingredients revenue share60% of H1 FY26 revenue
Pharma, food and nutrition revenue share40% of H1 FY26 revenue
NSS revenue contribution~₹20 cr in Q2
NSS EBITDA margin~30%
Net working capital days195 days as of 30 Sep 2025
Net debt₹73 cr, net debt-to-equity 0.1x as of 30 Sep 2025
Greenfield capex spent~₹120 cr of ₹150 cr outlay spent by Sep 2025
Overall capacity utilization~50% across all manufacturing
Pharma food and nutrition capacity utilization~65%, with optimum of 70%
NSS capacity utilization~35%
Gross margin63%-64% historical average, Q2 returned to this level after an exceptional FY25
US business subject to tariff50% subject to tariff, 50% exempted
H1 FY26 growth rate26%
Specialty ingredients CAGR since 202132%
R&D investment~2% of revenue
pCAM phase one capex~₹220 cr, including land and development
pCAM customer samplesOver 36 customers across US and Korea